2008
DOI: 10.1016/j.steroids.2008.02.010
|View full text |Cite
|
Sign up to set email alerts
|

Synthesis of exemestane labelled with 13C

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1

Citation Types

0
2
0

Year Published

2009
2009
2019
2019

Publication Types

Select...
6

Relationship

0
6

Authors

Journals

citations
Cited by 6 publications
(2 citation statements)
references
References 14 publications
0
2
0
Order By: Relevance
“…Two synthetic routes to [3,4- 13 C2]-enriched and [2,3,4- 13 C3]-enriched steroids have been previously reported. In the first one, the enone of the A-ring of ADD was opened either by ozonolysis followed by treatment with hydrogen peroxide or by oxidative cleavage with KMnO 4 /KIO 4 .…”
Section: Introductionmentioning
confidence: 99%
“…Two synthetic routes to [3,4- 13 C2]-enriched and [2,3,4- 13 C3]-enriched steroids have been previously reported. In the first one, the enone of the A-ring of ADD was opened either by ozonolysis followed by treatment with hydrogen peroxide or by oxidative cleavage with KMnO 4 /KIO 4 .…”
Section: Introductionmentioning
confidence: 99%
“…one 40 (Scheme 5). 29 Exemestane, marketed under the name Aromasinr® (FDA approval on October 21, 1999), was the first oral aromatase inactivator approved for the treatment of advanced breast cancer in postmenopausal women resistant to tamoxifen therapy. In this synthesis, the two 13 C atoms at C3 and C4 were incorporated using acylation of enol lactone 41 with [1,2-13 C 2 ]AcCl, followed by hydrolysis, decarboxylation, and cyclization to reconstruct the A ring.…”
Section: Syn Thesismentioning
confidence: 99%